Study title: Phase 3b, open-label, multicenter study designed to evaluate the efficacy and safety of topiramate as adjunctive therapy in pediatric subjects with inadequately controlled-seizures (with or without secondarily genralized seizures) seizures. Open label extension study of the safety and efficacy of rwj-17021-001 in subjects with bipolar disorder who completed topmat-pdmd-002. A placebo-controlled 12-week study of the safety and efficacy of one dose of topiramate versus lithium for the treatment of acute manic or mixed episodes in subjects with bipolar disorder I with an optional open-label extension.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Nervous System Diseases [C10] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: TOPIRAMATE | |||||
ATC code: N03AX11 | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |